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Aims Few data are available on the extent and prognostic value of reverse left ventricular remodelling (r-LVR) after
ST-elevation acute myocardial infarction (STEMI). We sought to evaluate incidence, major determinants, and long-term
clinical signiﬁcance of r-LVR in a group of STEMI patients treated with primary percutaneous coronary intervention
(PPCI).Inparticular,theroleofpreservedmicrovascularﬂowwithintheinfarctzoneininducingr-LVRhasbeeninvestigated.
Methods
and results
Serial echocardiograms (2DE) and myocardial contrast study were obtained within 24 h of coronary recanalization
(T1) and at pre-discharge (T2) in 110 reperfused STEMI patients. Follow-up 2DE was scheduled after 6 months
(T3). Two-year clinical follow-up was obtained. Reverse remodelling was deﬁned as a reduction .10% in LV end-
systolic volume (LVESV) at 6 months follow-up. r-LVR occurred in 39% of study population. At multivariable analysis,
independent predictors of r-LVR were an effective microvascular reﬂow within the infarct zone, the in-hospital
improvement of myocardial perfusion, an initial large LVESV, and a short time to reperfusion. Cox analysis identiﬁed
r-LVR as the only independent predictor of 2-year event-free survival. Combined events rate was signiﬁcantly higher
among patients without compared to those with r-LVR (log-rank test P , 0.05).
Conclusion r-LVR frequently occurs in STEMI patients treated with PPCI and it is an important predictor of favourable long-term
outcome. A preserved microvascular perfusion within the infarct zone is the major determinant of r-LVR.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
Keywords Myocardial contrast echocardiography † Acute myocardial infarction
Introduction
Left ventricle remodelling (LVR) is a relatively common and
unfavourable event occurring after acute myocardial infarction
(AMI).
1 The extent of microvascular damage after reperfusion has
been identiﬁed as one of the main determinant of this process.
2–5
On the other hand, the opposite phenomenon, LV volume
reduction after coronary reperfusion, known as reverse LVR
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doi:10.1093/eurheartj/ehn529(r-LVR), has been poorly investigated. A signiﬁcant r-LVR has been
recently described
6,7 after cardiac resynchronization therapy
(CRT) in patients with chronic heart failure and it is a strong pre-
dictor of longer long-term survival and less adverse cardiac
events.
7 r-LVR was also observed after ST-elevation acute myocar-
dial infarction (STEMI).
8–10However, few data are available on the
extent, determinants, and clinical signiﬁcance of r-LVR after STEMI
in modern clinical practice with a systematic use of primary percu-
taneous coronary intervention (PPCI) and ‘antiremodelling’ medi-
cations. This information might have important clinical
implications for the design and interpretation of trials aimed at
evaluating the efﬁcacy of new therapeutic options in patients
with STEMI.
11
Thus, we analysed the Acute Myocardial Infarction Contrast
Imaging (AMICI) multicenter study database
3 to investigate inci-
dence, major determinants, and long-term prognostic impact of
r-LVR in a group of STEMI patients treated with PPCI. Further-
more, as the extent of microvascular damage is one of the key
determinants of LVR
2–5,12,13 we assessed the role of microvascular
ﬂow changes after reperfusion in inducing r-LVR.
Methods
Study population
Details of AMICI study have been previously published.
3 In brief, con-
secutive patients referred to the catheterization laboratories of the
three centres involved in the study between January and November
2005, who underwent successful PPCI within 6 h of onset of STEMI
entered the AMICI trial. The Ethical Committee of the three Insti-
tutions involved approved the study, and all patients gave written
informed consensus to participate in the study.
Two-dimensional echocardiography (2DE) followed by myocardial
contrast study (MCE) was performed within 24 h of coronary recana-
lization (T1) and at pre-discharge (T2). Follow-up 2DE was scheduled
after 6 months (T3).
Echocardiography study
Two experienced observers analysed the echocardiographic data;
disagreement was resolved by consensus. The observers were blind
as for the time of echo images acquisition (admission, pre-discharge,
or follow-up) and for the patient’s identity. Regional LV Wall Motion
Score Index (RWMSI), end-diastolic (LVEDV) and end-systolic
(LVESV) LV volumes, and LV ejection fraction (LVEF) were calculated
as previously described (3.12.13). A percentage of the extent of wall
motion abnormalities (WMA%), as an index of the ischaemic
damage, was also calculated by dividing the number of akinetic and
dyskinetic segments by the total number of segments evaluated.
3,12,13
Regional LV dysfunction area was arbitrary deﬁned as large when
WMA% was .50, intermediate when WMA% was between 25 and
50, and small when WMA% was ,25%. Reverse remodelling was
deﬁned as .10% reduction in LVESV at 6 months follow-up
compared with 24 h echocardiogram.
7
Myocardial contrast echocardiography
Microvascular perfusion was assessed by real-time myocardial contrast
echocardiography (MCE) using continuous infusion of Sonovuew
(Bracco Imaging) as previously described.
3,12,13 In brief, a rotating infu-
sion pump (Vueject, Bracco Imaging, 2–4 vials at 78–180 mL/h infusion
rate) was used. Commercially available ultrasound systems equipped
with a real-time imaging package were used. A compromise between
power gain, dose and rate of contrast injection, and ﬂash duration was
achieved to obtain a completely dark myocardium after the ﬂash.
The settings of the echocardiograph were adjusted to optimize myo-
cardial opaciﬁcation and minimize attenuation artefacts. Instrument
settings, including power, gray-level compression (dynamic range),
gain, and frequency were kept constant until the end of the session.
For each patient, the previously optimized contrast settings were care-
fully matched for control MCE studies. MCE images were digitally
stored in a magneto-optical disk. The best MCE images were selected
for quantitative analysis of perfusion defect.
Qualitative analysis
The dysfunctional LV segments at baseline 2DE represented the area at
risk of necrosis. For analysis of myocardial perfusion, each initially
hypo, akinetic, or dyskinetic LV segment was graded using MCE
during simultaneously performed 2DE, 4-2-3-chamber apical views.
Poor or no opaciﬁcation was deﬁned as delayed, low, or absent
contrast enhancement in the evaluated segment when compared
with adjacent segments with adequate opaciﬁcation. A 17-segment
model of the left ventricle was used to assign the following contrast
scores: 1—homogeneous enhancement; 2—patchy enhancement;
3—no enhancement. A Regional Contrast Score Index (RCSI) was
calculated by dividing the sum of the contrast scores for each dysfunc-
tional segment by the number of dysfunctional segments analysed. In
case of disagreement over scoring, a consensus was reached after
open discussion.
Quantitative analysis
Quantitative analysis was performed on MCE images after coronary
reﬂow and at pre-discharge using Qontrastw Software (Bracco
Imaging), as previously described.
3,12,13 In brief, from native MCE
images, the length of the endocardial border corresponding to the
segment of the myocardium with no or poor opaciﬁcation was
measured in the 2-4- and 3-chamber views. The sum of endocardial
border length measurements deﬁned the size of the perfusion
defect. The following formula was used to assess the relative contrast
defect length (CDL%): (total length of residual contrast defect after
reperfusion)/(total length of endocardial border) 100.
Percutaneous coronary intervention and
medications
In all patients, PPCI and stenting of the infarct-related artery (IRA) was
performed according to the clinical protocol used at our insti-
tutions.
3,13 TIMI grade and myocardial blush grade were semi-
quantitatively scored as previously described.
3,13 Number of coronary
vessels showing signiﬁcant CAD was calculated.
Follow-up
After discharge, the clinical follow-up was achieved by means of a visit
at 6 months and a new visit or a phone interview at 2 years. Major
adverse cardiac events (MACE) were deﬁned as cardiac death
(deﬁned as sudden death caused by AMI or arrhythmia or heart
failure), non-fatal AMI (typical chest pain and increased troponin I),
and hospitalization for congestive heart failure. The diagnosis of
heart failure was based on clinical symptoms (limitation of activity,
fatigue, and dyspnoea), physical signs (oedema, elevated jugular
venous pressure, rales, or third heart sound with gallop), or radio-
logical evidence of pulmonary congestion.
7 For purposes of survival
analyses, only one event (the ﬁrst which occurred) was tabulated
for each patient.
Reverse remodelling in acute myocardial infarction 567Statistical analysis
The study sample size was powered to demonstrate a different value of
CDL% in predicting reverse LV remodelling. We calculated that 100
patients had to be enrolled to have an alpha error of 0.05, a power
of 0.80, a pooled variance of 320, and a mean difference of 5 in a pro-
spective cohort study. Mean and standard deviations were calculated
for quantitative variables and percentages for qualitative variables.
All variables were not-normally distributed and therefore differences
between groups were tested by Mann–Whitney test for quantitative
variables and by x
2 test for percentages of qualitative variables. A
repeated-measure analysis of variance was performed for all variables
using the generalized linear model, using the F-test (Pillai’s Trace)
as a statistical signiﬁcance test. The statistical signiﬁcance was set at
P   0.05 (two-sided tests), and for multiple testing we used a statistical
signiﬁcance of P   0.01.
All images were independently analysed by two experienced obser-
vers (L.A. and L.G.) who were blinded to the clinical data and of each
other’s results. To assess intra-observer variability of MCE and LV
volume analyses, 16 echo studies were independently reviewed by
the same observer (L.G.), 40+10 days after initial scoring. Inter-
observer variability was assessed by comparing the reading of the
two observers (L.G. and L.A.). Bland–Altman analysis was used.
For quantitative variables that showed a statistical signiﬁcant differ-
ence between the two groups (r-LVR vs. no LVR), receiver-operating
characteristic (ROC) curves were obtained to calculate the cutoff
values optimized to reach the best compromise in the prediction of
r-LVR. Optimal cutoff was deﬁned as the threshold where the sum
of sensitivity and speciﬁcity was maximum.
14 We used the bootstrap
method in order to characterize the variability of the adjusted esti-
mates of sensitivity and speciﬁcity using 95% conﬁdence intervals
(CIs) according to the methods developed by Efron and Tibshirani.
15
A multivariable logistic regression analysis was conducted considering
asdependentvariabletheoccurrenceofreverseremodellingatfollow-up.
All the variables presenting a signiﬁcant value ,0.25 at univariate analysis
were included in the model.The stepwise method withbackward elimin-
ation was used, and oddsratios (ORs)with 95% CIs were calculated. The
model was evaluated with Hosmer and Lemeshow test.
We have to consider that the results from any model could be too
optimistic when the model is used on the data set from which it has
been developed, and this could led to an overﬁtting. As one of the
main point of a research is the external validity, our aim was to
develop a model that can be used also for future patients. In order
to validate the ﬁnal model and to adjust (shrink) the regression coefﬁ-
cients (log ORs and log hazard ratio) for overﬁtting, a bootstrapping
technique was used.
16 In order to validate our ﬁnal logistic model,
we used the bootstrapping procedure performing a non-linear
regression, programming a maximum number of 999 iterations. This
procedure released the beta-coefﬁcients of the variables inserted in
the model, and we back-calculated the OR (and 95% CIs) through
an exponential transformation. The non-linear regression used in the
bootstrapping procedures was a generalized linear model for the
logistic regression. For the Cox analysis, we performed the boosting
procedure described by Li and Luan,
17 using the R package mboost
and the call gamboost (x, y, family ¼ CoxPH()) as suggested by
Hothorn and Buhlmann.
18
Considering the follow-up period, we were interested in identifying
baseline and pre-discharge predictors of MACE. We ﬁtted Cox
proportional-hazards models to estimate the unadjusted hazard
ratios (HRs) of all variables. All variables were considered with P ,
0.25 as the inclusion level. We analysed the incremental associations
of each variable to MACE beyond clinical variables (family history of
CAD and age). First of all, we built a multivariable Cox proportional-
hazards regression clinical model by a stepwise forward strategy to
select the strongest predictors associated with MACE. To assess the
incremental prognostic information from the ‘cardiac’ parameters
(r-LVR, WMA%-T1, LVESV-T1, and LVEDV-T1), we entered each of
these variables into the clinical models (for MACE) and used
likelihood-ratio (LR) tests to assess any signiﬁcant incremental prog-
nostic information beyond the clinical variables. In each of the ﬁnal
models, the validity of the proportional-hazards assumption was
tested by adding a time-dependent interaction variable for each of
the predictors in the models. This assumption was tested valid for
all the variables in the ﬁnal models. Finally, we validated our ﬁnal
model using the bootstrapping procedure, as described below for
the logistic regression model. Event-free survival curve for MACE
was constructed by use of the Kaplan–Meier method, and statistical
differences between curves were assessed by log-rank test. Statistical
analysis was performed with the use of the SPSS software package
for Windows 12.0 (SPSS, Inc., Chicago, IL).
Results
A total of 115 patients were enrolled, out of which ﬁve patients
were lost to 6-month follow-up. The remaining 110 patients
were considered for the ﬁnal analysis, and a 2-year follow-up
was obtained. No MACE occurred up to 6-month follow-up.
T1-2DE and MCE were performed 15+4 h from hospital admis-
sion and T2-2DE and MCE at 6+2 days from admission. T3-2DE
control was repeated at 22+3 weeks. Adequate MCE was
achieved in 95% of overall LV segments analysed at T1 and T2
(3553 out of 3740). All artefacts were excluded from the analysis.
More than half of the artefacts preventing assessment of MCE
occurred in the basal infero-posterior (16%), lateral (11%), and
anterior (28%) walls. There was high inter-observer and
intra-observer agreement in MCE and LV volume analyses accord-
ing to the Bland–Altman analysis (Table 1).
................................................................................
Table 1 Mean difference and 95% limits of agreement
(95% conﬁdence intervals) of values from echo analysis
comparing inter- and intra-observer variability at two
different time and for each observer (L.G. and L.A.)
Mean
difference
95% Limits of agreement (95% CIs)
CDL% 1 0.76 21.92 (22.13 to 21.70)–3.44 (3.21–3.66)
CDL% 2 20.42 22.34 (22.51 to 22.18)–1.50 (1.34–1.66)
CDL-LG 20.47 22.25 (22.49 to 22.02)–1.31 (1.09–1.54)
CDL-LA 0.71 21.83 (22.01 to 21.67)–3.25 (3.06–3.45)
LVESV 1 0.25 22.08 (22.12 to 22.04)–2.57 (2.53–3.62)
LVESV 2 1.00 21.82 (22.15 to 21.50)–3.82 (3.50–4.15)
LVESV-LG 20.75 25.13 (25.34 to 24.92)–3.63 (3.45–3.80)
LVESV-LA 0 22.82 (22.93 to 22.71)–2.82 (2.69–2.94)
LVEDV 1 0.13 24.30 (24.47 to 24.12)–4.45 (4.30–4.61)
LVEDV 2 20.5 25.16 (25.26to 25.05)– 4.16 (4.07–4.26)
LVEDV-LG 20.63 25.41 (25.54 to 25.27)–4.15 (4.03–4.28)
LVEDV-LA 0 23.20 (23.27to 23.12)– 3.20 (3.11–3.30)
CDL, contrast defect length; LVEDV, left ventricular end-diastolic volume;
LVESV, left ventricular end-systolic volume; CIs, conﬁdence intervals.
S. Funaro et al. 568At 6-month follow-up, 43 out of 110 patients (39%)
showed r-LVR (DLVESV 226+13%) with an incidence rate of
65.15/1000 person months (CI: 45.78–84.63). Baseline clinical,
angiographic, and echocardiographic characteristics in r-LVR
when compared with no r-LVR group were listed in Table 2.
There was no signiﬁcant difference in terms of age, gender, risk
factors, Killip class on admission, prevalence of multivessel coron-
ary artery disease, time from symptom onset to reperfusion,
anterior infarct site, and peak CK between groups; ST-segment
reduction after PCI was higher in the r-LVR group (P , 0.02).
Medications throughout hospital stay and during the follow-up
were similar between groups. No difference in TIMI and
myocardial blush grade 3 ﬂows after PCI was found. In particular,
there were no signiﬁcant differences between groups as for the
initial regional LV dysfunction area (RWMSI and WMA%), LV
volumes, and LVEF. The extent of microvascular damage (CDL%,
RCSI) on day 1 after reperfusion was signiﬁcantly lower in r-LVR
group.
Changes in contrast defect extent, LV volumes, regional LV
dysfunction, and LVEF over time were reported in Table 3.A tp r e -
discharge, only patients with r-LVR showed signiﬁcant improve-
ment in microvascular ﬂow with parallel decrease in dysfunctioning
area and improvement in LVEF. This functional improvement was
conﬁrmed at follow-up. In particular, a higher reduction in
...............................................................................................................................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
Table 2 Baseline clinical, angiographic, and echocardiographic parameters in the reverse left ventricular remodelling
(r-LVR) group when compared with the no reverse left ventricular remodelling (no r-LVR) group
r-LVR (43 pts) No r-LVR (67 pts) p
Mean age (years) 57+96 0 +11 0.24
Male, n (%) 38 (88) 54 (81) 0.861
Hypertension, n (%) 33 (77) 39 (60) 0.454
Diabetes, n (%) 4 (9) 19 (19) 0.082
Smokers, n (%) 30 (70) 39 (58) 0.671
Hypercholesterolaemia, n (%) 19 (44) 25 (37) 0.775
Family history of CAD, n (%) 12 (30) 17 (25) 0.991
ST-segment reduction (%) 65+33 42+51 0.02
Killip Class.1, n (%) 10 (24) 17 (26) 0.981
Concomitant medications, n (%)
ACE inhibitor/ARB 40 (94) 64 (96) 0.963
b-Blocker 39 (92) 62 (93) 0.944
Statins 40 (94) 65 (98) 0.992
Peak CK (Iul) 2019+1933 2505+1923 0.22
TIMI 3 ﬂow after PCI, n (%) 37 (87) 50 (76) 0.732
MBG 3 after PCI, n (%) 13 (30) 21 (32) 0.310
Infarct-related artery, n (%)
LAD 30 (70) 52 (78) 0.571
RCA 4 (9) 6 (9)
LCX 9 (21) 9 (13)
Vessels disease, n (%)
One 36 (83) 45 (68) 0.121
Two 4 (9) 15 (20)
Three 3 (7) 8 (12)
Time to reperfusion (h) 4.2+5 5.5+7 0.36
CDL%-T1 13+17 21+16 0.02
RCSI-T1 1.7+0.6 2+0.6 0.01
WMA%-T1 35+21 41+21 0.13
RWMSI-T1 2.6+0.7 2.7+0.5 0.17
LVEF%-T1 48+84 6 +9 0.35
LVEDV-T1 110+27 105+28 0.41
LVESV-T1 58+21 55+20 0.57
ACE, angiotensin-converting enzyme; ARB, angiotensin receptorblockers; CK, creatine kinase; TIMI, thrombolysis in myocardial infarction; MBG, myocardial blush grade; LAD, left
anterior descending; RCA, right coronary artery; LCX, left circumﬂex; CDL, contrast defect length; RCSI, regional contrast score imaging; WMA, wall motion abnormality;
RWMSI, Regional Wall Motion Score Index; LVEF, left ventricular ejection fraction; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume;
CAD, coronary artery disease. P-values in bold are signiﬁcant.
Reverse remodelling in acute myocardial infarction 569LVESV when compared with LVEDV was observed (226+13%
vs. 213+14%, respectively) leading to a signiﬁcant improvement
in LVEF at follow-up.
The extent of wall motion abnormality size was small in 32 out
of 110 (29%) patients, intermediate in 40 (36%), and large in 38
(35%). In these three groups, the prevalence of r-LVR was
similar (34, 35, and 32% respectively).
Independent predictors of reverse left
ventricular remodelling
Using the ROC curve analysis, optimal cutoff values of different
parameters in the prediction of r-LVR were identiﬁed (Table 4).
The in-hospital reduction in CDL  15% is the parameter with
the best sensitivity and speciﬁcity in predicting r-LVR (71 and
75%, respectively, AUC 0.731, P ¼ 0.0002).
At multivariate analysis, age ,64 years [OR 3.25 (95% CI: 0.9–
11.68), P ¼ 0.071], initial extent of microvascular damage after
reperfusion ,20% [OR ¼ 15.59 (95% CI: 3.27–74.38), P ¼
0.001], initial LVESV .60 ml [OR ¼ 7.93 (95% CI: 1.75–35.8),
P ¼ 0.007], time to treatment [OR ¼ 3.35 (95% CI: 0.99–11.28),
P ¼ 0.051], and in-hospital CDL reduction  15% [OR ¼ 4.57
(95% CI: 1.05–19.79), P ¼ 0.042] were independently associated
with r-LVR (Table 5). After bootstrapping procedure, only the fol-
lowing variables were associated with r-LVR: CDL-T1 [OR ¼ 9.90
(95% CI: 3.34–29.27], LVESV-T1 [OR ¼ 2.85 (95% CI: 0.93–8.64],
time to treatment [OR ¼ 2.74 (95% CI: 1.06–7.06], and DCDL
[OR ¼ 3.84 (95% CI: 1.02–14.44].
For the logistic regression, the optimal solution was found after
eight major iterations. The bootstrap statistics were based on 150
samples.
Two-year survival
In up to 2-year follow-up, four patients (3.6%) had non-fatal
re-infarction, nine (8.2%) were hospitalized for heart failure, and
three (2.7%) had cardiac death. According to the Kaplan–Meier
curves, patients with r-LVR had a signiﬁcantly higher 2-year event-
free survival rate (log-rank test P , 0.05) than those without r-LVR
(Figure 1). Hazard ratios of all variables entered into the Cox
model were listed in Table 6. By multivariable Cox analysis, inde-
pendent predictors of MACE were: family history of CAD [HR
3.42 (1.18–9.88)], age [HR 3.15 (0.98–1018)], r-LVR [HR 0.50
(0.18–1.38)], and LVESV-T1 [HR 1.02 (1.00–1.05)] (Table 7).
After bootstrapping procedure, the only variable signiﬁcantly
associated with a 2-year event-free survival was r-LVR
[HR ¼ 0.28 (0.12–0.66)].
Discussion
The AMICI multicenter study demonstrates for the ﬁrst time that
r-LVR frequently occurs in STEMI patients treated with PPCI. The
relatively short time to IRA recanalization with stenting implan-
tation, the systematic use of downstream glycoprotein IIB/IIIA
inhibitors with double-antiplatelet therapy, and the widespread
use of statins and antiremodelling medications may explain these
positive results. A signiﬁcant reduction of LV volumes may be
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.
S. Funaro et al. 570observed even in patients with large risk area soon after reperfu-
sion, thus showing that r-LVR is independent of initial dysfunction-
ing area extent. For the ﬁrst time, we provide cutoff values of
parameters able to offer the best diagnostic accuracy in the predic-
tion of r-LVR. The major determinant of r-LVR is an effective
microvascular reﬂow within the infarct zone (CDL% ,20%).
Also the reduction in microvascular damage in the ﬁrst week
after recanalization ( 15%), an initial large end-systolic volume
(.60 mL), and a short time to treat (,2.5 h) independently
predict reverse remodelling. r-LVR has a strong clinical impact
because only in this subset of patients a signiﬁcant improvement
in LVEF and a signiﬁcant reduction in deﬁnitive infarct size have
been observed at follow-up. Further, this subset of patients had
a signiﬁcantly lower combined events rate at 2-year follow-up
than patients without r-LVR.
Future studies aimed at evaluating the effects of new therapeutic
interventions in STEMI patients have to take into account this
spontaneous improvement in myocardial perfusion and function
occurring up to 6 months after myocardial infarction.
Previous studies
Ventricular enlargement after myocardial infarction is an adaptive
compensatory mechanism to maintain stroke volume after the loss
of contractile function. Several studies show that the extent of sub-
sequent LV volume enlargement reﬂects the magnitude of the
primarymicrovasculardamage.
2–5,8–10Conversely,littleinformation
is available on the incidence, determinants, and clinical signiﬁcance of
r-LVR after STEMI. Previous large multicentre trials showed that
pharmaceutical agents, including ACE inhibitors and b-blockers,
attenuate rather than reverse LVR, with a few notable excep-
tions.
8–10 The GISSI 3 study showed for the ﬁrst time a signiﬁcant
LV volume reduction after myocardial infarction. However, determi-
nants and clinical signiﬁcance of this phenomenon were not
described.
10 The SAVE study
19 and most recently the VALIANT
and the CAPRICORN studies
20,21 demonstrated the linkage
between attenuation of LV enlargement by captopril, valsartan, or
carvedilol after infarction and improved clinical outcomes. Recently,
ithasbeendemonstratedthatr-LVRmayoccuraftercoronaryrevas-
cularizationinpatients withischaemiccardiomyopathy
8 orevenafter
...............................................................................................................................................................................
Table 4 Receiver-operating characteristic curve analysis
Cutoff value
(95% CI)
Sensitivity
(%)
95%
CI (*)
Speciﬁcity
(%)
95%
CI (*)
AUC 95% CI P-value
Age ,64 (,59 to ,69) 74 58.8–86.5 (57–93) 39 27.1–51.5 (21–59) 0.563 0.465–0.657 0.2585
ST reduction >59 (>53 to >65) 70 53.0–84.1 (51–90) 58 43.2–71.3 (39–77) 0.656 0.548–0.754 0.0088
Peak CK ,3026 (,2998 to
,3055)
85 70.2–94.3 (69–99) 40 27.0–54.1 (21–60) 0.590 0.485–0.690 0.1223
Vessels disease ¼1 83 69.3–93.2 (68–99) 27 17.0–39.6 (6–53) 0.538 0.440–0.634 0.4993
TIMI grade ¼3 87 72.6–95.7 (71–100) 23 14.0–36.2 (5–48) 0.556 0.454–0.654 0.3442
MBG ¼2 70 51.3–84.4 (49–92) 32 20.0–47.5 (13–56) 0.535 0.422–0.646 0.5871
Time to
reperfusion
 2.5 ( 1.7 to
 3.4)
60 43.3–74.4 (39–83) 65 51.6–76.9 (47–85) 0.591 0.489–0.687 0.1074
CDL%-T1 <20 (<15 to <26) 70 53.9–82.8 (50–91) 61 48.5–72.9 (44–83) 0.635 0.538–0.725 0.0110
RCSI-T1 <2( <1.1 to 3) 60 44.4–75.0 (38–85) 53 41.1–66.0 (35–74) 0.626 0.529–0.717 0.0182
WMA%-T1 ,41 (,28 to ,55) 65 49.1–79.0 (44–88) 56 44.0–68.8 (36–78) 0.580 0.482–0.674 0.1458
RWMSI-T1 ,2.82 (,1.23 to
,4.44)
46 31.2–62.3 (25–70) 73 60.9–83.2 (58–89) 0.579 0.481–0.672 0.1522
LVEF%-T1 .42 (.39 to .45) 81 66.6–91.6 (65–98) 31 20.6–43.8 (11–55) 0.557 0.459–0.651 0.3182
LVEDV-T1 .104 (.82 to
.127)
58 42.1–73.0 (37–82) 56 44.0–68.8 (21–58) 0.554 0.457–0.649 0.3380
LVESV-T1 .60 (.33 to .86) 44 29.1–60.1 (23–68) 67 54.6–78.1 (50–83) 0.526 0.428–0.622 0.6532
CDL%-T2 <19 (<16 to <23) 81 66.6–91.6 (64–99) 54 41.1–66.0 (35–75) 0.682 0.586–0.767 0.0003
RCSI-T2 <1.8 (<1.5 to 2) 74 58.8–86.5 (55–95) 58 45.5–70.1 (40–77) 0.695 0.600–0.780 0.0001
WMA%-T2 <41 (<38 to <44) 83 69.3–93.2 (68–99) 48 35.4–60.3 (28–69) 0.654 0.558–0.742 0.0031
RWMSI-T2 <2.1 (<1.5 to
<2.8)
58 42.1–73.0 (37–81) 80 69.1–89.2 (66–94) 0.659 0.563–0.747 0.0021
LVEF%-T2 >49 (>40 to >58) 67 51.5–80.9 (45–92) 60 47.0–71.5 (39–80) 0.639 0.542–0.729 0.0114
LVEDV-T2 ,105 (,89 to
,120)
70 53.9–82.8 (50–92) 57 44.0–68.8 (33–81) 0.603 0.505–0.695 0.0579
LVESV-T2 <50 (<36 to <55) 60 44.4–75.0 (38–84) 62 50.0–74.2 (47–79) 0.627 0.530–0.718 0.0170
DCDL% <215 (<221 to
<210)
71 47.8–88.6 (44–99) 75 61.1–86.6 (58–92) 0.731 0.612–0.830 0.0002
*95% bootstrap bias-corrected conﬁdence interval.
Abbreviations as in Table 2.
Reverse remodelling in acute myocardial infarction 571late reopening of an occluded IRA
9 and is closely related to the
extentofviablemyocardiumintheinfarctzone.Similarly,asigniﬁcant
correlation was found between total scar burden at baseline and
r-LVR after 6 months of CRT in patients with ischaemic cardiomyo-
pathy.
22 The total scar burdenasdetected byMCEisanindependent
predictor of long-term hard cardiac events in patients after AMI.
14
Accordingly, our study showed that an effective microvascular
reﬂow within the infarct zone soon after reperfusion is a key deter-
minant of r-LVR and of long-term event-free survival. However,
independently of dysfunctioning area soon after IRA reopening,
the improvement of microvascular perfusion in the ﬁrst week after
hospital admission is a strong predictor of r-LVR at follow-up. In
patients with r-LVR, a signiﬁcant recovery of microvascular ﬂow
was detected during the ﬁrst week after STEMI (DCDL –38%).
Similar improvement in microvascular ﬂow after reperfusion has
been previously reported.
23,24 Although there are no deﬁnitive
explanations for this phenomenon, we can postulate that it might
be the result of resolution of potentially reversible mechanisms of
microvascular obstruction such as arteriolar spasm, tissue oedema,
and cellular plugging.
23,24 The improvement in microvascular ﬂow
may also be related to spontaneous angiogenesis occurring in the
ﬁrst week after reperfusion. An up-regulation of circulating endo-
thelialprogenitorcells(EPCs)knowntobeinvolvedinvasculogenesis
has been recently detected in the ﬁrst week after primary stenting.
25
The EPCs mobilized after AMI may contribute to new vessel gener-
ation and are closely related to a greater increase in myocardial
salvage, decrease in LVESV, and recovery of LVEF.
26
Similar data have been recently reported by Ndrepepa et al.
27
They showed in the majority of STEMI patients treated by PPCI
a substantial improvement in LVEF at 6-month follow-up mainly
............................................ ..........................................
...............................................................................................................................................................................
Table 5 Multiple logistic regression analysis for predictors of reverse left ventricular remodelling
Variables Cutoff value (95% CI) Univariable analysis Multivariable analysis
OR (95% CI) P OR (95% CI) P
Age ,64 1.845 (0.79–4.28) 0.155 3.25 (0.9–11.68) 0.071
Sex Male 1.83 (0.60–5.56) 0.287
Hypertension No 0.042 (0.17–0.99) 0.049
Diabetes No 2.34 (0.71–7.74) 0.161
Hypercholesterolaemia No 0.752 (0.34–1.63) 0.473
Smokers No 0.604 (0.26–1.35) 0.223
Family history of CAD No 0.878 (0.37–2.08) 0.769
Time to treatment ,2.5 2.56 (1.13–5.82) 0.024 3.35 (0.99–11.28) 0.051
Culprit lesion LAD 0.66 (0.27–1.58) 0.358
RCA 1.04 (0.27–3.93) 0.951
LCX 1.70 (0.61–4.71) 0.303
ST reduction (%) .59 2.758 (1.131–6.723) 0.026
Peak CK ,3026 3.77 (1.36–10.49) 0.011
TIMI grade after PCI ¼3 2.125 (0.70–6.40) 0.181
MBG after PCI ¼3 0.89 (0.34–2.32) 0.823
Vessels disease 1 2.4 (0.91–6.27) 0.074
WMA%-T1 ,41 1.99 (0.91–4.33) 0.082
RWMSI-T1 ,2.82 1.96 (0.87–4.41) 0.104
CDL%-T1 ,20 3.639 (1.610–8.225) 0.002 15.59 (3.27–74.38) 0.001
RCSI-T1 ,2 1.776 (0.816–3.864) 0.148
LVEF%-T1 .42 1.99 (0.79–5) 0.143
LVESV-T1 .60 1.619 (0.736–3.564) 0.231 7.93 (1.75–35.8) 0.007
LVEDV-T1 .104 1. 820 (0.838–3.950) 0.130
WMA%-T2 ,41 3.38 (1.48–7.7) 0.004
RWMSI-T2 ,2.18 5.769 (2.450–13.587) 0.000
CDL%-T2 ,19.33 5.08 (2.05–12.57) 0.000
DCDL% ,215 2.22 (0.93–5.32) 0.072 4.57 (1.05–19.79) 0.042
RCSI-T2 ,1.8 4.052 (0.750–9.382) 0.001
LVEF%-T2 .49 3.069 (1.374–6.862) 0.006
LVESV-T2 ,50 2.569 (1.170–5.643) 0.019
LVEDV-T2 ,105 3.024 (1.344–6.802) 0.007
Hosmer–Lemeshow test x
2 ¼ 9.151 0.242
CI, conﬁdence interval; OR, odds ratio; DCDL%, in-hospital contrast defect length changes. Other abbreviations as in Table 2.
S. Funaro et al. 572Figure 1 Kaplan–Meier curves showing patients with r-LVR
had a signiﬁcantly higher 2-year event-free survival rate
(log-rank test P , 0.05) than those without r-LVR.
........................................
................................................................................
Table 6 Unadjusted hazard ratios for major adverse
cardiac events
Variables MACE (n 5 16)
HR (95% CI) P-value
Age 1.025 (0.978–1.074) 0.240
Male 0.799 (0.269–2.40) 0.690
Hypertension 0.763 (0.29–2.007) 0.583
Diabetes 0.739 (0.171–3.200) 0.686
Hypercholesterolaemia 1.162 (0.457–2.951) 0.755
Smokers 0.846 (0.340–2.103) 0.718
Family history of CAD 2.454 (0.987–6.105) 0.053
Time to treatment 1.555 (0.356–6.801) 0.558
Anterior wall AMI 1.576 (0.653–2.153) 0.576
ST reduction (%) 1.007 (0.991–1.022) 0.720
Peak CK 1.003 (1.012–1.034) 0.881
TIMI grade after PCI 1.555 (0.356–6.801) 0.558
MBG after PCI 1.120 (0.621–2.026) 0.706
Number of diseased vessels 1.173 (0.651–2.113) 0.595
WMA%-T1 1.024 (1–1.049) 0.053
RWMSI-T1 0.994 (0.460–2.148) 0.987
CDL%-T1 1.011 (0.985–1.037) 0.411
RCSI-T1 1.240 (0.647–2.377) 0.517
LVEF%-T1 0.947 (0.896–1.001) 0.556
LVESV-T1 1.025 (1.006–1.045) 0.012
LVEDV-T1 1.015 (1–1.030) 0.054
r-LVR 0.605 (0.230–1.593) 0.240
CI, conﬁdence interval; HR, hazard ratio; r-LVR, reverse left ventricular
remodelling; AMI, acute myocardial infarction. Other abbreviations as in Table 2.
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.
Reverse remodelling in acute myocardial infarction 573related to a progressive decrease in the perfusion defect. These
changes have a beneﬁcial effect on long-term survival.
In conclusion, the improvement of microvascular perfusion after
STEMI is possible; it is independent of the initial extent of LV dys-
function and is a strong determinant of signiﬁcant LV volume
reduction and regional and global LV function improvement.
Future studies aimed at assessing the efﬁcacy of new angiogenetic
drugs should take into account these spontaneous changes in
microvascular ﬂow occurring up to 6 months after STEMI.
Clinical implications
A reduction in LVESV of 10% has recently identiﬁed
7 as the optimal
cutoff value to predict long-term survival after CRT in patients with
congestive heart failure thus signifying a clinically relevant reverse
LVR. In our study population with AMI, a mean reduction at
follow-up in LVESV of 26+13% and in LVEDV of 13+14% was
observed, and was closely related to global and regional LV
function improvement (DLVEF þ 12%, DWMA –40%) and to
long-term prognosis. These beneﬁcial effects have been achieved
in patients timely treated with primary IRA stenting and IIB/IIIA gly-
coprotein inhibitors. Further, large part of the study population
received optimal medical therapy that includes ACE/ARBs,
statins, and b-blockers and further support the importance of
the use of these drugs after myocardial infarction. A recent
meta-analysis
11 showed a lesser efﬁcacy of bone-marrow-derived
cell therapy on cardiac function (mean reduction in infarct size
25.5%, in LVESV 24.8%, and in LVEDV 21.9%). Thus the
effects of cell-based cardiac repair therapy may be masked by
the powerful effect of reperfusion therapy and concomitant
treatment.
Study limitations
The study population is relatively small and the 2-year event rate is
low, thus the relationship between r-LVR and clinical outcome
need to be conﬁrmed in larger longitudinal studies. Patients
enrolled in this study were optimally treated, thus the incidence
or r-LVR in high-risk STEMI sub-optimally treated cannot be
derived. However, the multicentre randomized design of the
study adds strength to the results, and the data set collected
allows drawing conclusions with sufﬁcient statistical power. We
have not performed quantitative analysis of the replenishment
curves of MCE data because we believe that in the setting of
AMI and for the purpose of the study these data did not add sig-
niﬁcant meaning to our results. On the other hand, we elected to
quantify the length of MCE perfusion defect, which is the best indi-
cator of the extent of microvascular damage and the ideal par-
ameter able to inﬂuence LV remodelling.
2–5,12,13,24 Finally, not all
variables involved in determining dynamic changes in LV function
and shape after AMI were considered in this study. In particular,
the role of diastolic dysfunction, transmural extent of necrosis,
and neurohormonal activation in preventing r-LVR need to
clariﬁed by future studies.
Conclusions
A substantial number of STEMI patients treated according to the
current guidelines show a signiﬁcant reverse LVR. This volume
reduction is an important predictor of favourable long-term clinical
outcome.
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Cerebral embolism from subclinical carotid atherosclerotic lesion
in a young woman with inﬂammatory Crohn disease
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A 39-year-old woman was hospitalized
for sudden massive left haemiplegia.
Her only risk factor was light smoking.
She was diagnosed with Crohn disease
1 month before, and treated with corti-
coids. Early angio-computed tomo-
graphic (CT) scan and magnetic
resonance imaging (MRI) showed large
sylvian cerebral ischaemia, right sylvian
artery thrombosis and suggested the
existence of intraluminal right carotid
bulb abnormality (Panel A). Ultrasound
examination reﬁned the abnormality as
beingalargemobilethrombusadherent
to the posterior wall of the right bulb
(Panel B). She was treated with heparin
leading to lysis of the thrombus 7 days
later (Panel C). A small plaque at the
site of previous thrombus adhesion
was visualized. After 1 month of Cou-
madin treatment, ultrasound conﬁrmed
the presence of a tiny ulcerated plaque
(Panel D).
Laboratory investigations showed evidence of systemic inﬂammation. Traditional risk factors were normal. Serological examination
for vasculitis-associated antibodies was negative.
Few cases of cerebrovascular complications in patients with Crohn disease have been published and were related to
Crohn-associated vasculitis and/or consequence of hypercoagulability. Evidence of atherosclerotic aetiology has never been previously
shown. Atherosclerosis is a chronic disease of the arterial wall where inﬂammation is central at all stages. This case illustrates the
mechanism of stroke in a young woman with active inﬂammatory Crohn disease and high pro-thrombotic condition, due to small
atherosclerotic plaque ulceration and thrombus embolization. It emphasizes the prominent role of carotid ultrasound in such cases.
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org.
Reverse remodelling in acute myocardial infarction 575